Get the Stockscreener App
1.55
1.52%
-0.024
After Hours:
1.54
-0.01
-0.65%
Heartbeam Inc stock is traded at $1.55, with a volume of 95,171.
It is down -1.52% in the last 24 hours and down -6.63% over the past month.
HeartBeam Inc is a medical technology company primarily focusing on developing and commercializing higher resolution ambulatory Electrocardiogram ("ECG") solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The Company's ability to develop higher-resolution ECG solutions is achieved through the development of the Company's proprietary and patented Vector Electrocardiography ("VECG") technology platform. The Company has validated this technology and is seeking U.S. Food and Drug Administration ("FDA") clearance for its initial telehealth products.
See More
Previous Close:
$1.574
Open:
$1.56
24h Volume:
95,171
Relative Volume:
1.31
Market Cap:
$52.41M
Revenue:
-
Net Income/Loss:
$-14.47M
P/E Ratio:
-1.25
EPS:
-1.24
Net Cash Flow:
$-12.19M
1W Performance:
-12.43%
1M Performance:
-6.63%
6M Performance:
-32.31%
1Y Performance:
-26.54%
1-Day Range:
$1.55
$1.62
1-Week Range:
$1.52
$1.8288
52-Week Range:
$1.45
$3.48
Heartbeam Inc Stock (BEAT) Company Profile
Name
Heartbeam Inc
Sector
Industry
Phone
408-899-4443
Address
2118 WALSH AVE., SUITE 210, SANTA CLARA
Compare BEAT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BEAT
Heartbeam Inc
|
1.55 | 59.69M | 0 | -14.47M | -12.19M | -1.24 |
|
VEEV
Veeva Systems Inc
|
242.78 | 38.63B | 2.75B | 714.14M | 1.09B | 4.33 |
|
TEM
Tempus Ai Inc
|
65.49 | 10.62B | 803.32M | -709.10M | -212.68M | -7.8003 |
|
HQY
Healthequity Inc
|
98.23 | 7.82B | 1.15B | 96.70M | -161.99M | 1.09 |
|
DOCS
Doximity Inc
|
52.56 | 11.11B | 550.17M | 201.35M | 232.07M | 1.00 |
|
WAY
Waystar Holding Corp
|
39.34 | 6.92B | 906.14M | -52.62M | 89.62M | -0.3621 |
Heartbeam Inc Stock (BEAT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-11-20 | Initiated | Needham | Buy |
| Sep-02-20 | Initiated | Robert W. Baird | Neutral |
| Jan-08-20 | Initiated | SunTrust | Buy |
| Aug-02-19 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Apr-26-19 | Reiterated | Dougherty & Company | Buy |
| Jul-26-18 | Reiterated | Lake Street | Buy |
| Apr-26-18 | Reiterated | The Benchmark Company | Buy |
| Feb-23-18 | Reiterated | Dougherty & Company | Buy |
| Nov-08-17 | Reiterated | Dougherty & Company | Buy |
| Oct-26-17 | Initiated | Raymond James | Outperform |
| Oct-24-17 | Initiated | SunTrust | Buy |
| Aug-09-17 | Reiterated | Dougherty & Company | Buy |
| Jul-19-17 | Reiterated | The Benchmark Company | Buy |
| Apr-11-17 | Reiterated | Dougherty & Company | Buy |
| Dec-02-16 | Initiated | Dougherty & Company | Buy |
| Sep-13-16 | Initiated | Sidoti | Buy |
| Aug-03-16 | Reiterated | The Benchmark Company | Buy |
| Jul-28-15 | Reiterated | Dougherty & Company | Buy |
| Oct-24-13 | Initiated | The Benchmark Company | Buy |
| Aug-21-13 | Initiated | Dougherty & Company | Buy |
View All
Heartbeam Inc Stock (BEAT) Latest News
Benchmark maintains $8 target on Heartbeam stock post-1Q report By Investing.com - Investing.com India
HeartBeam’s Positive Earnings Call Reflects Growth Potential - TipRanks
HeartBeam, Inc. (NASDAQ:BEAT) Q1 2025 Earnings Call Transcript - Insider Monkey
HeartBeam (NASDAQ: BEAT) Hits FDA Milestone and Expands Strategic Partnerships in Q1 Update - Barchart.com
HeartBeam (BEAT) Reports Advancements in Q1 2025 | BEAT Stock Ne - GuruFocus
HeartBeam reports net loss of USD 5.5M in Q1 2025 - Medical Buyer
HeartBeam, Inc. Reports Q1 2025 Financial Results - TipRanks
Earnings call transcript: HeartBeam Q1 2025 miss doesn’t deter investors By Investing.com - Investing.com India
Heartbeam Inc reports results for the quarter ended March 31Earnings Summary - TradingView
HeartBeam Q1 2025 slides: FDA progress and commercial readiness amid continued losses - Investing.com India
HeartBeam, Inc. SEC 10-Q Report - TradingView
HeartBeam Reports First Quarter 2025 Results - Business Wire
The Week in Canadian Press Releases: 10 Stories You Need to See - The Globe and Mail
HeartBeam strengthens IP with US patents for cardiac monitoring - Yahoo Finance
Two New U.S. Patents Bring Total to 20 Issued Worldwide, - openPR.com
Two New U.S. Patents Bring Total to 20 Issued Worldwide, Cementing Company Leadership in Cardiac Monitoring Innovation for 12-Lead ECG Synthesis Technology: HeartBeam, Inc. (Nasdaq: BEAT) - Barchart.com
HeartBeam Secures 2 New U.S. Patents - Medical Product Outsourcing
HeartBeam (NASDAQ: BEAT) Adds Two U.S. Patents to Bolster Cardiac Monitoring IP Portfolio - Barchart.com
HeartBeam (BEAT) Expands IP Portfolio with New U.S. Patents | BEAT Stock News - GuruFocus
HeartBeam Announces Two New U.S. Patents, Powering Forward Its Robust Patent Portfolio - Business Wire
HeartBeam Expands Board with CEO Robert Eno’s Appointment - citybuzz -
HeartBeam (NASDAQ: BEAT) Appoints CEO Robert Eno To Board Of Directors - Barchart.com
HeartBeam (BEAT) Welcomes CEO Robert Eno to Its Board of Directo - GuruFocus
HeartBeam Appoints CEO Robert Eno to Board - TipRanks
HeartBeam expands board, appoints CEO to director role By Investing.com - Investing.com India
HeartBeam expands board, appoints CEO to director role - Investing.com Australia
HeartBeam Appoints CEO Robert Eno to Board of Directors to Support U.S. Commercialization and Growth - Bluefield Daily Telegraph
HeartBeam, Inc. Appoints Robert Eno to Board of Directors - marketscreener.com
HeartBeam (NASDAQ: BEAT) Appoints CEO Robert Eno to Board of Directors - The Globe and Mail
HeartBeam (NASDAQ: BEAT) Prices $10 Million Public Offering At $1.70 Per Share - Barchart.com
HeartBeam (NASDAQ: BEAT) to Report Q1 2025 Results and Provide Business Update on May 13 - Barchart.com
HeartBeam to Host First Quarter 2025 Results Conference Call on Tuesday, May 13, 2025 at 4:30 p.m. Eastern Time - Bluefield Daily Telegraph
HeartBeam’s ECG technology shows promise in study for arrhythmia diagnosis - Yahoo Finance
HeartBeam Successfully Meets Clinical Endpoints in Pivotal Study for its Groundbreaking 12-Lead ECG Synthesis Technology - BioSpace
Strategic Collaboration with AccurKardia for Ambulatory ECG - openPR.com
Strategic Collaboration with AccurKardia for Ambulatory ECG Recording and Analysis to Advance Cardiac Monitoring Care: HeartBeam, Inc. (Nasdaq: BEAT) - The Globe and Mail
Strategic Collaboration with AccurKardia for Ambulatory ECG Recording and Analysis to Advance Cardiac Monitoring Care: HeartBeam, Inc. (Nasdaq: BEAT) | FinancialContent - FinancialContent
HeartBeam (NASDAQ: BEAT) Reports Positive VALID-ECG Study Results Supporting 12-Lead ECG Tech - Barchart.com
HeartBeam’s VALID-ECG Study of 12-Lead ECG Synthesis Tech Meets Endpoints - Medical Product Outsourcing
HeartBeam (BEAT) Achieves Key Milestones with Synthesized 12-Lea - GuruFocus
HeartBeam’s ECG software shows promise in clinical study - Investing.com
HeartBeam’s ECG software shows promise in clinical study By Investing.com - Investing.com India
HeartBeam announces VALID-ECG pivotal study met primary endpoint - TipRanks
HeartBeam, AccurKardia Announce Strategic Collaboration - Diagnostic and Interventional Cardiology
HeartBeam names new auditor after Marcum resignation By Investing.com - Investing.com Nigeria
HeartBeam names new auditor after Marcum resignation - Investing.com
HeartBeam partners with AccurKardia to enhance cardiac care - Yahoo Finance
HeartBeam and AccurKardia partner on ECG tech By Investing.com - Investing.com South Africa
HeartBeam (NASDAQ: BEAT) And AccurKardia Partner To Advance Remote ECG Monitoring - Barchart.com
HeartBeam, AccurKardia Begin Cardiac Monitoring Partnership - Medical Product Outsourcing
HeartBeam and AccurKardia partner on ECG tech - Investing.com
Heartbeam Inc Stock (BEAT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.94%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):